18 December 2020 | 14:25pm StockMarketWire.com - Braveheart Investment Group said work by its investee company Paraytec to develop a Covid-19 test is ‘proceeding at pace’. Paraytec has acquired purified SARS-CoV2 virus which it will use to optimise both the lower limit and speed of detection, with the aim of detecting the virus in asymptomatic or pre-symptomatic patients. Ethical approval has been obtained from the Sheffield Hospitals Trust to test up to 500 clinical samples, which will be verified using the gold standard PCR approach to demonstrate the performance characteristics of the Covid-19 test. The first results of this work are expected by the end of January 2021. Braveheart notes the recent discussions in the media regarding the underperformance of a range of single-use testing (lateral flow) devices, which are being trialled throughout the UK.